DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE:
AGN), a leading global biopharmaceutical company, today announced
it will establish an R&D presence in the Kendall Square section
of Cambridge, Massachusetts, a hub
of science, innovation and business opportunities. The site will be
led by Don Frail, PhD, Senior Vice President of Research and
External Scientific Innovation (RESI) and Non-Clinical and
Translational Sciences.
"One of the driving sources of innovation today comes from
smaller biotechnology and pharma companies. Our new, strategic
presence in Kendall Square will allow us to more easily interact
and engage with venture firms and start ups in the area," said
David Nicholson, EVP & Chief
R&D Officer. "I am confident that our new location in
Cambridge, along with Don's deep
expertise will accelerate the evaluation of scientific
opportunities and further deliver on our Open Science model and the
next wave of potentially transformational medicines."
Dr. Frail joined Allergan in 2014, relocating from Boston to the Allergan R&D center in
Irvine, CA, and has led the
Research, Clinical Pharmacology, Toxicology and ADME departments
including the External Science & Innovation initiatives to
evaluate and implement partnerships and acquisitions across
Allergan's four key therapeutic areas. Don will continue to lead
the Irvine team as well.
Previously, Frail led the Emerging Innovations Unit at AstraZeneca,
the Indications Discovery Units at Pfizer and the CNS Discovery
organization at Pharmacia.
"I'm looking forward to returning to the Boston area to establish Allergan's new
presence where we will continue to identify cutting-edge
technologies and opportunities that deliver the highest value to
patients and their healthcare providers. Our Irvine site will continue to be the home of
R&D and retain its long-established External Scientific
Innovation and Non-Clinical Translational Sciences team. The new
Cambridge group will be fully
integrated with the Allergan organization, and serve as a portal to
our other R&D sites in Madison
NJ, San Francisco area, and
globally," said Don Frail, PhD.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures;
uncertainty associated with financial projections, projected cost
reductions, projected debt reduction, projected synergies,
restructurings, increased costs, and adverse tax
consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2017
and Allergan's Quarterly Report on Form 10-Q for the period ended
September 30, 2018. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Manisha Narasimhan,
PhD
|
|
(862)
261-7162
|
|
|
|
Christine
Chiou
|
|
(862)
261-7396
|
|
|
|
Karina
Calzadilla
|
|
(862)
261-7328
|
|
|
|
Media:
|
|
Amy Rose
|
|
(862)
289-3072
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-to-establish-rd-presence-in-cambridge-massachusetts-300773586.html
SOURCE Allergan plc